Blueprint Medicines (BPMC) Stifel 2024 Healthcare Conference summary

Company evolution and commercial performance

• Expanded focus in 2024 to allergy immunology, anchored by Ayvakit's global launch in systemic mastocytosis (SM), now exceeding $500M in annual revenue and targeting multi-billion-dollar peak sales.

• Pipeline includes a next-generation KIT inhibitor for lifecycle extension and BLU-808, a wild-type KIT inhibitor in phase one, with data expected early next year and plans for multiple proof-of-concept studies.

• Strong commercial execution and focused investment have reduced operating cash burn, positioning the company well for 2025.

Market dynamics and growth drivers

• Diagnosis rates for SM are rising rapidly, with recent data suggesting disease prevalence may be double previous estimates, fueling continued market expansion.

• Prescriber breadth and depth are increasing, with more specialties like dermatology showing interest, and patient mix remains consistent as diagnosis grows.

• International revenue, led by Germany, is growing and expected to remain 10–15% of total, with more markets coming online in 2025.

Guidance and outlook

• 2024 revenue guidance for ISM was raised by over $100M above initial expectations, reflecting strong performance.

• Guidance philosophy emphasizes realism and adaptability, with updated ranges provided as more data becomes available; 2025 guidance will be issued with Q4 results.